bluebird bio, Inc. (NASDAQ:BLUE – Get Rating) CEO Andrew Obenshain sold 21,805 shares of the company's stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $4.39, for a total transaction of $95,723.95. Following the completion of the transaction, the chief executive officer now owns 247,131 shares in the company, valued at approximately $1,084,905.09. The sale was disclosed in a legal filing with the SEC, which is available through this link.

bluebird bio Stock Up 13.4 %

BLUE traded up $0.75 during trading on Monday, hitting $6.34. The company's stock had a trading volume of 10,617,046 shares, compared to its average volume of 4,637,974. The business's 50 day simple moving average is $4.22 and its 200-day simple moving average is $4.76. The firm has a market cap of $453.02 million, a PE ratio of -0.74 and a beta of 1.29. bluebird bio, Inc. has a one year low of $2.87 and a one year high of $25.39.

bluebird bio (NASDAQ:BLUE – Get Rating) last announced its earnings results on Monday, May 9th. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.40). bluebird bio had a negative return on equity of 130.19% and a negative net margin of 2,141.34%. The company had revenue of $1.95 million during the quarter, compared to the consensus estimate of $0.17 million. During the same period in the prior year, the business posted ($3.07) earnings per share. bluebird bio's revenue for the quarter was up 117.6% compared to the same quarter last year. Equities research analysts expect that bluebird bio, Inc. will post -5.07 EPS for the current fiscal year.

Hedge Funds Weigh In On bluebird bio

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Raymond James upgraded shares of bluebird bio from a "market perform" rating to an "outperform" rating and set a $8.00 target price on the stock in a research note on Tuesday, August 2nd. Wedbush cut their target price on bluebird bio from $10.00 to $8.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 10th. Morgan Stanley reduced their target price on bluebird bio to $3.00 and set an "underweight" rating for the company in a report on Tuesday, May 17th. Finally, Barclays raised bluebird bio from an "underweight" rating to an "equal weight" rating and increased their price objective for the company from $3.00 to $5.00 in a research report on Friday. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $11.86.

About bluebird bio

(Get Rating)

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.

Featured Stories

• Get a free copy of the StockNews.com research report on bluebird bio (BLUE)
• How to Use the MarketBeat Dividend Calculator
• Two Appealing Biotech Stocks for Two Distinct investors
• Is Tyson Foods A Buy On Post-Earnings Weakness?
• Is DoorDash Ready To Sprint Higher?
• Electric Vehicles Can Drive Alcoa Stock Higher

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.